Catalyst Dossier · compiled by Celia 🧫

AbbVie Inc. (ABBV)

Pharmaceutical Preparations · market cap $382.5B · as of 2026-06-23

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-15 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

AbbVie Inc. (ABBV) is a large-cap pharmaceutical company with ~$382B market cap, $61.2B in 2025 revenue, and a diversified pipeline spanning immunology, oncology, ophthalmology, and neurology. The company carries significant net debt of ~$55.1B but generates substantial operating cash, with R&D spend of ~$9.1B in 2025. The near-term catalyst setup is unusually dense, with multiple Phase 2 and Phase 3 readouts clustered between July and December 2026.

The catalyst path

2026-07-15 (est.)Phase 3 · Bimatoprost SRimp 9/10
2026-07-15 (est.)Phase 2 · Mirvetuximab Soravtansineimp 7/10
2026-07-30Earningsimp 5/10
2026-08-15 (est.)Phase 3 · ABBV-444imp 9/10
2026-08-15 (est.)Phase 2 · Ranibizumabimp 7/10
2026-09-15 (est.)Phase 3 · adalimumabimp 9/10
2026-10-15 (est.)Phase 3 · Aflibercept (EYLEA®)imp 9/10
2026-11-15 (est.)Phase 2 · ABBV-932imp 7/10

Pipeline

Asset	Phase	Indication
AGN-242428	Phase 2	Dry Eye Disease
ABBV-8E12	Phase 2	Alzheimer's Disease
Bimatoprost (SR)	Phase 3	Open-Angle Glaucoma
etanercept	Phase 3	Moderate to Severe Plaque Psoriasis
ABT-450	Phase 2	Hepatitis C Virus
Azacitidine	Phase 3	Acute Myeloid Leukemia (AML)
Etentamig	Phase 3	Multiple Myeloma
ABBV-382	Phase 2	Crohn's Disease
Acalabrutinib	Phase 3	Chronic Lymphocytic Leukemia
Ustekinumab	Phase 3	Psoriasis
Temozolomide	Phase 3	Glioblastoma
ABT-981	Phase 2	Erosive Hand Osteoarthritis
Dupilumab	Phase 3	Atopic Dermatitis
Elagolix	Phase 3	Polycystic Ovary Syndrome
Obinutuzumab	Phase 3	Chronic Lymphocytic Leukemia (CLL)
ABT-SLV187	Phase 3	Advanced Parkinson's Disease
Ranibizumab	Phase 2	Neovascular Age-Related Macular Degeneration (nAMD)
Carboplatin	Phase 3	High Grade Ovarian Cancer
ABT-450/r/ABT-267, ABT-333	Phase 3	Chronic Hepatitis C Infection
Paricalcitol	Phase 3	Chronic Kidney Disease Stage 3 and 4

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by Celia. The catalyst path & pipeline above are free.

See Pro

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by Celia. Not financial advice.